Longduoduo provides preventive healthcare solutions in the People's Republic of China. Treatment projects include ozone autologous blood transfusion (immunotherapy), Xingnao Tongluo therapy, double blood purification, and platelet-rich plasma (PRP) injection therapy. The company primarily conducts its business in the domestic market.
Cyborg Score Rationale
Longduoduo operates in a niche preventive healthcare market in China with OTC listing and minimal analyst coverage (0 analysts). The company lacks transparency typical of larger healthcare providers and market data is limited, indicating weak institutional support and liquidity challenges.
Top Insights
OTC-listed healthcare provider with no analyst coverage, limiting institutional adoption and price discovery
Specialized focus on cardiovascular and cerebrovascular disease prevention through alternative therapies differentiates from mainstream hospitals but creates regulatory and market acceptance risks
Purely domestic China operations expose the company to regulatory changes and limited expansion opportunities outside competitive home market
Stock price volatility significant (52-week range $1.37–$6.05), suggesting liquidity constraints and high risk profile typical of microcap OTC equities
Named Competitors
Traditional Hospital Networks — State-owned and private hospital chains offering integrated preventive care
Cardiovascular Screening Services — Independent medical examination and disease screening platforms
Open the full interactive Longduoduo Co Ltd report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.